Seven studies (745 participants, range 18 to 296) were included in the review: two randomised controlled trials and five single group open label trials. One study was described as double-blind. Five trials were full publications and two were abstracts.
All trials showed statistically significant improvement with tamsulosin in female lower urinary tract symptoms (especially in women with predominant voiding dysfunction) as well as improvements in quality of life and sleep quality.
Adverse events, where reported, included dizziness and asthenia, stress incontinence and urgency, fatigue, drowsiness and hypotension. The prazosin group reported dizziness, orthostatic hypotension, headache and blurred vision.